The gene editing market is projected to grow massively by 2030 owing to rising demand for gene synthesis and CRISPR technologies. In addition, technological advancements, coupled with growing investment in R&D activities, are speculated to further propel market growth through the forecast timespan.
Recently, the COVID-19 pandemic has impacted the market positively as gene editing technologies allow the detection of SARS-CoV-2 and the alteration of defected genes in plants and animals. Prominent technological advancements in the market have positively influenced the overall product landscape.
Recently, in May 2022, a Nature Nanotechnology study aimed to enhance CRISPR/Cas9 gene editing by modulating cellular mechanical properties for the treatment of cancer. It concluded that modulating the stiffness of the tumor tissue can help in improving gene editing in tumors, offering a new strategy for cancer treatment with gene editing.
Moreover, government initiatives to encourage research and development activities for the treatment of genetic disorders have fueled gene editing market growth. For instance, in May 2022, the U.S. Food and Drug Administration (FDA) awarded fast-track designation to biotech firm Graphite Bio’s GPH101, a gene editing therapy that has been developed to correct genetic mutation caused by sickle cell disease.
Furthermore, key participants in the industry have been focusing on technological innovation in gene editing therapies, along with effective growth strategies, to prosper in the market. To quote an instance, in May 2022, U.S. FDA granted Orphan Drug Designation to EDIT-301, an experimental gene editing therapy by clinical-stage biotech company Editas Medicine to treat beta thalassemia.
The gene editing market has been bifurcated based on end-user, application, technology, and region. In terms of application, the market has been categorized into animal genetic engineering, plant genetic engineering, cell line engineering, and others. The cell line engineering segment is slated to expand at a CAGR of more than 15.3% through the forecast period due to the widespread application of cell line engineering.
With reference to technology, the gene editing industry has been divided into zinc finger nucleases (ZFNs), TALENs, CRISPR/Cas9, and others. The CRISPR/Cas9 segment held around 47% market share in 2021 and is set to grow prominently up to 2030 owing to the rise in CRISPR technology preference due to its several benefits.
With regards to end-user, the market has been segregated into contract research organizations (CROs), research institutes, and biotech and pharma companies. The biotech and pharma companies segment surpassed $2.4 billion valuation in 2021 and is speculated to register substantial gains through 2030. Increasing focus of biopharmaceutical companies on developing advanced gene editing technologies is likely to fuel segmental growth over the review timespan.
In the regional frame of reference, the Latin America gene editing market accounted for over 11.1% of the overall industry revenue in 2021. This growth is attributed to mounting incidences of genetic disorders across several countries in the LATAM region.